Figure 1From: CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients Correlation between the trend in serial CA15-3 measurements and PETCT findings. The bar plot shows the mean CA15-3 serum levels at 0–3, 3–6, and 6–9 months prior to PETCT. Dotted line indicates CA15-3 cut-off (25 UI/mL). The P-value was determined with an unpaired t-test.Back to article page